Drug intelligence / Profile preview

UBP-Her2-CART

Development stage: Preclinical
Lead developer: UWELL Biopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UBP-Her2-CART (also known as UWHer2T) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed by UWELL Biopharma for the treatment of HER2-positive solid tumors. The therapy involves engineering a patient's T cells to express a CAR that specifically recognizes and binds to the Human Epidermal Growth Factor Receptor 2 (HER2) on the surface of tumor cells, leading to T-cell activation and targeted tumor cell lysis. As of 2024, the program is in the preclinical stage, specifically listed under CAR engineering in the developer's pipeline.

Other names: UWHer2TUWHer-2TUWHer 2T

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on UBP-Her2-CART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBP-Her2-CART.

Explore the full profile